A novel 4-gene prognostic signature for hypermutated colorectal cancer

BACKGROUND: Hypermutated colorectal cancer (CRC) reportedly accounts for 15%–17% of all cases of CRC. However, the proportion and number of patients with hypermutated CRC cannot be unappreciated. Additionally, therapy options for these patients differ from those for CRC patients, with a greater pote...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Weiting, Cai, Wen, Bai, Rui, Hu, Wangxiong, Wu, Dehao, Zheng, Shu, Hu, Hanguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407520/
https://www.ncbi.nlm.nih.gov/pubmed/30881123
http://dx.doi.org/10.2147/CMAR.S190963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407520/
https://www.ncbi.nlm.nih.gov/pubmed/30881123
http://dx.doi.org/10.2147/CMAR.S190963

Ejemplares similares